GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Armed with $75m the company takes a risky asset into the clinic.
The biotech licenses a China-developed anti-B7-H3 ADC.
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
GEN1286 looks dead, though MCLA-129 continues for now.
And the company says it won’t need to carry out another trial.
